In the realm of cancer treatment, immunotherapy has recently come to the forefront as a promising area, with Immune Checkpoint Inhibitors (ICIs) such as anti-PD1, anti-programmed death ligand-1 (PD-L1), and anti-cytotoxic T-lymphocyte antigen-4 (CTLA-4) in treating ccRCC [9–11]. This evidence concerns the gene PDCD1 and nonpapillary renal cell carcinoma.